Supriya Lifescience DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Supriya Lifesciences Saloni & Shivani Wagh in Candere Hurun India

07 Jun 2025

// EXPRESSPHARMA

Supriya Lifescience expands solar power capacity with 5 MWp facility

19 Mar 2025

// EXPRESSPHARMA

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

28 Jan 2025

// INDPHARMAPOST

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI WW Frankfurt

Booth #12.0F99

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

6 Corporate Content #SupplierSpotlight, 1 Data Compilation #PharmaFlow, 51 News #PharmaBuzz

media
6 Corporate Content #SupplierSpotlight
1 Data Compilation #PharmaFlow
51 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

90 All APIs, 18 USDMF, 10 CEP/COS, 1 JDMF, 25 EU WC, 35 KDMF, 32 NDC API, 48 Listed APIs

90 All APIs
18 USDMF
10 CEP/COS
1 JDMF
25 EU WC
35 KDMF
32 NDC API
48 Listed APIs

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

117 FDF Dossiers, 117 Listed Dossiers

117 FDF Dossiers
117 Listed Dossiers

KEY PRODUCTS

ATS-8, Bisoprolol Fumarate, Cetirizine Dihydrochloride, Iohexol, Lisdexamfetamine Dimesylate, Sevoflurane, Tramadol Hydrochloride

ATS-8
Bisoprolol Fumarate
Cetirizine Dihydrochloride
Iohexol
Lisdexamfetamine Dimesylate
Sevoflurane
Tramadol Hydrochloride

INSPECTIONS & REGISTRATIONS

3 FDA, 2 EDQM, 1 WHO-GMP, 2 GDUFA

inspections
3 FDA
2 EDQM
1 WHO-GMP
2 GDUFA

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

About

Supriya Lifescience Limited is a globally recognized, technology-driven manufacturer of APIs , CDMO & formulations, established in 1987. Headquartered in Mumbai, India, we operate a 3 times USFDA, 2 times EUGMP, Health Canada & numerous other regulatory approved API facility in Lote & a state-of-the-art formulation site in Ambernath. Founded by Dr. Satish Wagh, we are global leaders in therapeutic segments like antihistamines, antiallergics, vitamins, anesthetics, & anti-asthmatics. With a presence in over 86 countries and serving 1500+ customers, we are your trusted partner with 15+ USDMFs, 10+ CEPs, & a manufacturing capacity of 1050 KL.

CPhI KoreaCPhI Korea

Industry Trade Show

Not Confirmed

26-28 August, 2025

COEX, Seoul, Korea
CPhI WW FrankfurtCPhI WW Frankfurt

Industry Trade Show

Booth #12.0F99

28-30 October, 2025

Frankfurt
CPhI IndiaCPhI India

Industry Trade Show

Booth #1.B12

25-27 November, 2025

India Expo Centre, Greater Noida

CONTACT DETAILS

Click the arrow to open the dropdown

Country

India

Address

207/208 Udyog Bhavan, Sonawala Road, Goregoan [E], Mumbai – 400 063

Telephone

+91 2226860012

supriya@supriyalifescience.com

Website

https://supriyalifescience.com/

https://www.linkedin.com/company/supriya-lifescience-limited/

YouTube

https://www.youtube.com/@SupriyaLifescience/videos

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

FDF Product List 2024

Open PDF

Upload

API Product List 2025

GMP Certificate 2023

Corporate Video

DATA COMPILATION #PharmaFlow

Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17 13 37 Taiwan 9 6 5 4 24 Switzerland 15 4 4 23 France 16 6 22 Japan 18 1 19 United Kingdom 12 1 2 15 Mexico 9 1 1 11 Ireland 5 5 1 11 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years.

Impressions: 14025

NEWS #PharmaBuzz

Supriya Lifesciences Saloni & Shivani Wagh in Candere Hurun India

07 Jun 2025

// EXPRESSPHARMA

Supriya Lifescience expands solar power capacity with 5 MWp facility

19 Mar 2025

// EXPRESSPHARMA

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

28 Jan 2025

// INDPHARMAPOST

Union Budget 2025-26: roadmap for India’s pharmaceutical leadership

26 Jan 2025

// EXPRESSPHARMA

Supriya opens new API block at Lote Parshuram site in Maharashtra

18 Dec 2024

// ECONOMICTIMES

Supriya Lifescience expands global footprint with Esketamine HCL

11 Dec 2024

// PRESS RELEASE

ALL APIs

Click the button for full data set

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Supriya Lifescience

India

CPhI WW Frankfurt

Booth #12.0F99

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Lead Product(s) : Undisclosed

Therapeutic Area : Trauma (Emergency, Injury, Surgery)

Highest Development Status : Preclinical

Partner/Sponsor/Collaborator : Kalinga Institute of Technology

Deal Size : Undisclosed

Deal Type : Agreement

DEALS_DEV

Supriya Lifescience Signs Agreement with KIT for Further Development of Wound Healing Gel

Details : Through the agreement, Supriya Lifescience will focus on the advancement of GelHeal, a protein-based crosslinked Hydrogel, gel-based cream, which is being evaluated for the treatment of deep wounds.

Product Name : GelHeal

Product Type : Other Large Molecule

Upfront Cash : Undisclosed

November 06, 2023

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02 Supriya Lifescience

India

CPhI WW Frankfurt

Booth #12.0F99

Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Lead Product(s) : Bucillamine

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Revive Therapeutics

Deal Size : Undisclosed

Deal Type : Collaboration

DEALS_DEV

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

Details : Revive Therapeutics and Indian specialty pharma firm, Supriya Lifescience have signed an MOU to pursue the manufacturing of the API, conduct clinical registration, and commercialize Bucillamine in the treatment of mild-to-moderate COVID-19 in India.

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

June 08, 2021

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]